Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    Atorvastatin Improves Dyslipidaemia in Patients With Coronary Heart Disease, May Be Renoprotective: Presented at Renal Week 2009 - (DGDispatch)
    Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents - (JAMA)
    TopAbstracts in Cholesterol/Lipid Disorders 10/29/2009 - (DGNews)
    Addition of Ezetimibe Helps More Elderly Achieve LDL Cholesterol Goal Than Uptitration of Atorvastatin: Presented at CCC - (DGDispatch)
    New Canadian Cholesterol-Lowering Guidelines Target Immediate-Risk Group: Presented at CCC - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
    • Optimizing Management of Dyslipidemia: Risk Assessment, Treatment Targets, and Adherence
    • Assessing Cardiovascular Risk
    • Setting Treatment Goals for Primary Prevention of Cardiovascular Disease
    • Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Ispaghula Husk Nearly As Effective As Simvastatin For Hyperlipidemia

        A DGReview of :"A Comparative Evaluation of Ispaghula Husk (Dietary Fiber) and Simvastatin in Hyperlipidemic Indian Patients"
        Indian Heart Journal

        12/24/2002
        By James Adams


        Ispaghula husk (psyllium) is nearly as effective as simvastatin for improving the lipid profile of hyperlipidemic patients.

        It is also much cheaper and has fewer side effects than does simvastatin, report investigators from the Government Medical College in Amritsar, India.

        The investigators randomized 60 hyperlipidemic patients into two groups of 30. One group received 3.5 grams of ispaghula husk twice a day and the second group received 20 milligrams of simvastatin each day. Treatment continued for 12 weeks, and lipid profiles were evaluated at 0, 4, 8 and 12 weeks.

        Results showed that total cholesterol decreased by 15.8 percent and low-density lipoprotein (LDL) cholesterol decreased by 22.97 percent among patients taking ispaghula husk.

        Triglycerides decreased by 20.89 percent and high-density lipoprotein (HDL) cholesterol increased by 10.69 percent in these patients.

        Among patients taking simvastatin, total cholesterol decreased by 24.15 percent, LDL cholesterol decreased by 36.08 percent, triglycerides decreased by 20.47 percent and HDL cholesterol increased by 11.4 percent.

        Mild gastrointestinal disturbances were reported by 23.34 percent of the ispaghula husk patients. Feelings of cold in the joints and diuresis were each reported by 6.67 percent of ispaghula husk patients.

        In the simvastatin group, 26.66 percent reported mild gastrointestinal disturbance, 16.67 percent reported mild myalgia and 6.67 percent experienced insomnia.

        Ispaghula husk is an effective and well-tolerated dietary adjunct for patients with hyperlipidemia and should be considered before initiating conventional drug therapy, the investigators conclude.

        They point out that larger and longer studies are required to determine the long-term benefits of ispaghula husk.
        Indian Heart Journal 2002; 54(5). "A Comparative Evaluation of Ispaghula Husk (Dietary Fiber) and Simvastatin in Hyperlipidemic Indian Patients"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send